Daily Cosmetic Research Analysis
Today's top studies span perioperative infection prevention, nanomaterial safety relevant to cosmetic ingredients, and updated adult atopic dermatitis therapies. A large multicenter analysis found no benefit of preoperative chlorhexidine bathing for fracture surgery, while in vitro mechanistic data linked zinc oxide nanoparticles to blood-brain barrier dysfunction. Updated guidelines strongly recommend new topical and biologic agents for adult atopic dermatitis.
Summary
Today's top studies span perioperative infection prevention, nanomaterial safety relevant to cosmetic ingredients, and updated adult atopic dermatitis therapies. A large multicenter analysis found no benefit of preoperative chlorhexidine bathing for fracture surgery, while in vitro mechanistic data linked zinc oxide nanoparticles to blood-brain barrier dysfunction. Updated guidelines strongly recommend new topical and biologic agents for adult atopic dermatitis.
Research Themes
- Perioperative infection prevention strategies
- Nanotoxicology and cosmetic ingredient safety
- Guideline updates in dermatologic therapy
Selected Articles
1. Chlorhexidine Gluconate Bathing Has Limited Ability to Prevent Surgical Site Infection Following Operative Fixation of Extremity and Pelvic Fractures.
In a secondary analysis of 10,103 fracture surgery patients from the PREP-IT trials, preoperative chlorhexidine bathing did not reduce 90-day surgical site infections after adjustment and instrumental variable analyses. Findings argue against routine CHG bathing in the trauma fracture setting.
Impact: This large multicenter analysis challenges a common infection-prevention practice and can inform de-implementation and resource allocation in trauma surgery.
Clinical Implications: Routine preoperative CHG bathing may be unnecessary for extremity/pelvic fracture fixation; focus should shift to proven SSI prevention bundles (e.g., timely antibiotics, antiseptic skin prep, normothermia).
Key Findings
- Among 10,103 fracture surgery patients, 26% received a preoperative CHG bath while 74% did not.
- No significant reduction in 90-day SSI with CHG bathing in multivariable analysis (OR 1.07; 95% CI, 0.86–1.32; p=0.56).
- Instrumental variable analysis comparing high- versus low-use sites also showed no benefit (OR 0.88; 95% CI, 0.62–1.25; p=0.48).
Methodological Strengths
- Large, prospectively collected multicenter dataset derived from cluster-randomized crossover trials.
- Use of both multivariable adjustment and instrumental variable analysis to mitigate confounding.
Limitations
- Exposure to CHG bathing was not randomized; residual confounding and selection bias are possible.
- Potential variability in bathing protocols and adherence; secondary analysis limits causal inference.
Future Directions: Conduct pragmatic randomized trials or stepped-wedge implementations to test CHG bathing in trauma, and evaluate cost-effectiveness within comprehensive SSI prevention bundles.
BACKGROUND: A preoperative chlorhexidine gluconate (CHG) bath is used to reduce the risk of surgical site infection (SSI) in elective surgery, but its efficacy in the trauma setting is unknown. We compared the incidence of SSI between patients who did versus did not receive a CHG bath before operative fixation of extremity and/or pelvic fractures. METHODS: We conducted a secondary analysis of the PREP-IT cluster-randomized crossover trials that enrolled patients undergoing operative treatment for open or closed extremity or pelvic fractures. Preoperative CHG bathing (yes or no) was recorded for each patient per study protocol. The association between CHG bathing and SSI within 90 days after definitive fracture surgery was assessed. We performed multivariable regression to adjust for prognostic variables. We also conducted a separate instrumental variable analysis to compare SSI rates between study sites that used CHG bathing for >90% of participants and those that used CHG bathing for <1% of participants. RESULTS: Of the 10,103 participants (mean age, 51 ± 20 years; 47% female; 77% White; 17% Black; 4% Asian; 7% Hispanic) included in the analysis, 2,674 (26%) had a documented preoperative CHG bath and 7,429 (74%) did not. CHG bathing was not associated with a significant reduction in the odds of 90-day SSI in the multivariable (odds ratio [OR], 1.07; 95% confidence interval [CI], 0.86 to 1.32; p = 0.56) or instrumental variable (OR, 0.88; 95% CI, 0.62 to 1.25; p = 0.48) analyses. CONCLUSIONS: Among adult patients who underwent extremity or pelvic fracture surgery, preoperative CHG bathing was not associated with a significant reduction in SSI. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
2. Iron overload and oxidative stress participated in zinc oxide nanoparticles-induced blood-brain barrier dysfunction.
In brain endothelial cells, ZnO nanoparticles accumulated in lysosomes, triggered ferroptosis and oxidative stress, and drove hyperpermeability via intracellular iron overload and dysregulated autophagy. The authors propose an adverse outcome pathway for BBB disruption by ZnO-NPs, informing safety assessments of widely used cosmetic and sunscreen ingredients.
Impact: Provides mechanistic insight linking ZnO nanoparticles to BBB dysfunction through ferroptosis and iron overload, a critical safety consideration for nanomaterials used in cosmetics and sunscreens.
Clinical Implications: While translational confirmation is needed, formulators and regulators should consider particle size, surface coatings, and dosing to mitigate iron-dependent toxicity when using ZnO nanoparticles in topical products.
Key Findings
- ZnO-NPs accumulated in lysosomes and promoted ferroptosis in bEnd.3 brain endothelial cells after 9-hour exposure.
- Oxidative stress led to lysosomal dysfunction and cytotoxicity, with intracellular iron overload driving dysregulated autophagy and endothelial hyperpermeability.
- A putative adverse outcome pathway for BBB disruption by ZnO-NPs was proposed to guide risk assessment.
Methodological Strengths
- Multiparametric mechanistic assessment including ferroptosis, lysosomal function, autophagy, and permeability endpoints.
- Use of a relevant brain endothelial cell model and integration into an adverse outcome pathway framework.
Limitations
- In vitro single-cell-line model with acute exposure; lacks in vivo confirmation and dose–response at consumer-relevant exposures.
- Does not evaluate formulation context (e.g., surface coatings, agglomeration) common to real-world sunscreen products.
Future Directions: Validate findings in in vivo BBB models and evaluate how particle size, charge, and coatings alter ferroptosis and permeability; assess safety within realistic topical formulations.
Since zinc oxide nanoparticles (ZnO-NPs) are widely used, concerns about their potential human health effects are growing. Although ZnO-NPs, due to their nano-size, can cross the blood-brain barrier (BBB) and affect brain function, the potential risk of ZnO-NPs in brain endothelial cells, the major components of the BBB, is largely unknown. In brain endothelial cells (bEnd.3 cells), ZnO-NPs were exposed for 9 h to evaluate the brain endothelial dysfunction and BBB disruption. ZnO-NPs were deposited in the lysosome and promoted ferroptosis in bEnd.3 cells. Increased oxidative stress led to lysosomal dysfunction and cytotoxicity in bEnd cells treated with ZnO-NPs.3 cells. ZnO-NPs induced dysregulated autophagy flux and hyperpermeability via intracellular iron overload in bEnd.3 cells. We developed a putative adverse outcome pathway (AOP) to understand the effects of ZnO-NPs on the function of brain endothelial cells. Our study will help clarify the potential impact and toxicity of ZnO-NPs on the brain endothelium and the BBB.
3. Focused update: Guidelines of care for the management of atopic dermatitis in adults.
This focused update issues strong recommendations for tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab (with concomitant topical therapy) in adult atopic dermatitis, based on a systematic review and GRADE methodology. Most underlying RCTs are short in duration, limiting long-term comparisons.
Impact: Guideline updates rapidly translate emerging evidence into practice, expanding therapeutic options with clear, graded recommendations.
Clinical Implications: Clinicians can consider adding tapinarof or roflumilast creams as steroid-sparing topicals and escalate to lebrikizumab or nemolizumab in appropriate adults, while monitoring long-term effectiveness and safety.
Key Findings
- Strong recommendation for tapinarof cream as a topical option in adult AD.
- Strong recommendation for roflumilast cream as a topical option in adult AD.
- Strong recommendations for lebrikizumab and nemolizumab with concomitant topical therapy.
Methodological Strengths
- Systematic review underpinning recommendations with GRADE assessment of certainty.
- Multidisciplinary guideline panel and transparent grading of recommendations.
Limitations
- Most underlying RCTs are short-term, limiting conclusions about long-term efficacy and safety.
- Guideline scope focuses on adults; pediatric generalizability may be limited.
Future Directions: Head-to-head and long-term comparative effectiveness studies across new topicals and biologics; real-world safety and cost-effectiveness in diverse populations.
BACKGROUND: In 2023 and 2024, the American Academy of Dermatology published guidelines on the use of topical and systemic therapies for the management of atopic dermatitis (AD) in adults. Since the publication of these guidelines, several novel therapies have emerged to treat AD. OBJECTIVE: To update previous guidelines on the management of AD in adults by providing evidence-based recommendations on the use of additional Food and Drug Administration-approved topical and systemic therapies. METHODS: A multidisciplinary workgroup conducted a systematic review and applied the Grading of Recommendations, Assessment, Development, and Evaluation approach for assessing the certainty of evidence and formulating and grading recommendations. RESULTS: The workgroup developed 4 new recommendations for the management of AD in adults. LIMITATIONS: This analysis is based on the best available evidence at the time it was conducted. Most randomized controlled trials of the considered therapies for AD are of short duration, limiting comparative long-term efficacy and safety conclusions. CONCLUSIONS: The workgroup developed strong recommendations for the use of tapinarof cream, roflumilast cream, lebrikizumab, and nemolizumab with concomitant topical therapy.